All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Phase I ZUMA-4 trial: Long-term follow-up of brexu-cel in pediatric/adolescent R/R B-ALL

During the EHA2021 Virtual Congress, the ALL Hub spoke with André Baruchel, Hôpital Robert-Debré, Paris, FR, about the long-term follow-up from the ZUMA-4 trial.

Phase I ZUMA-4 trial: Long-term follow-up of brexu-cel in pediatric/adolescent R/R B-ALL

In this video, Baruchel analyzes the results from the ZUMA-4 trial (NCT02625480) evaluating brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R B-ALL). KTE-X19 is an autologous anti-CD19 chimeric antigen receptor T-cell therapy. He discusses patient characteristics, dosage, safety, efficacy, and toxicities, such as cytokine release syndrome and neurological adverse events.